530 related articles for article (PubMed ID: 29482894)
21. Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time.
Nakar C; Shapiro A
Transfus Apher Sci; 2019 Oct; 58(5):578-589. PubMed ID: 31447396
[TBL] [Abstract][Full Text] [Related]
22. New predictive approaches for ITI treatment.
Minno GD; Santagostino E; Pratt K; Königs C
Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
[TBL] [Abstract][Full Text] [Related]
23. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors.
Sakurai Y; Shima M; Tanaka I; Fukuda K; Yoshida K; Yoshioka A
Haematologica; 2004 Jun; 89(6):696-703. PubMed ID: 15194537
[TBL] [Abstract][Full Text] [Related]
24. The importance of inhibitor eradication in clinically complicated hemophilia A patients.
Oldenburg J; Young G; Santagostino E; Escuriola Ettingshausen C
Expert Rev Hematol; 2018 Nov; 11(11):857-862. PubMed ID: 30286680
[TBL] [Abstract][Full Text] [Related]
25. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
26. Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?
Varthaman A; Lacroix-Desmazes S
Haematologica; 2019 Feb; 104(2):236-244. PubMed ID: 30514798
[TBL] [Abstract][Full Text] [Related]
27. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
28. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Rangarajan S; Jiménez-Yuste V; Santagostino E
Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
[No Abstract] [Full Text] [Related]
29. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
30. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.
Lapalud P; Rothschild C; Mathieu-Dupas E; Balicchi J; Gruel Y; Laune D; Molina F; Schved JF; Granier C; Lavigne-Lissalde G
J Thromb Haemost; 2015 Apr; 13(4):540-7. PubMed ID: 25603934
[TBL] [Abstract][Full Text] [Related]
31. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
32. Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators.
Karim AF; Soltis AR; Sukumar G; Königs C; Ewing NP; Dalgard CL; Wilkerson MD; Pratt KP
Front Immunol; 2020; 11():1219. PubMed ID: 32595650
[TBL] [Abstract][Full Text] [Related]
33. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
Matino D; Gargaro M; Santagostino E; Di Minno MN; Castaman G; Morfini M; Rocino A; Mancuso ME; Di Minno G; Coppola A; Talesa VN; Volpi C; Vacca C; Orabona C; Iannitti R; Mazzucconi MG; Santoro C; Tosti A; Chiappalupi S; Sorci G; Tagariello G; Belvini D; Radossi P; Landolfi R; Fuchs D; Boon L; Pirro M; Marchesini E; Grohmann U; Puccetti P; Iorio A; Fallarino F
J Clin Invest; 2015 Oct; 125(10):3766-81. PubMed ID: 26426076
[TBL] [Abstract][Full Text] [Related]
34. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.
Scott DW; Pratt KP
Front Immunol; 2019; 10():3078. PubMed ID: 32010137
[TBL] [Abstract][Full Text] [Related]
35. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
Ay Y; Ersin T; Yesim O; Hilkay KT; Dilek I; Gulcihan O; Ahmet K
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
[TBL] [Abstract][Full Text] [Related]
36. Progress toward inducing immunologic tolerance to factor VIII.
Scott DW; Pratt KP; Miao CH
Blood; 2013 May; 121(22):4449-56. PubMed ID: 23502223
[TBL] [Abstract][Full Text] [Related]
37. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.
Earnshaw SR; Graham CN; McDade CL; Spears JB; Kessler CM
Haemophilia; 2015 May; 21(3):310-319. PubMed ID: 25688580
[TBL] [Abstract][Full Text] [Related]
38. Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors.
Doshi BS; Raffini LJ; George LA
J Thromb Haemost; 2020 Apr; 18(4):848-852. PubMed ID: 31985872
[TBL] [Abstract][Full Text] [Related]
39. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
40. The role of VWF for the success of immune tolerance induction.
Kreuz W
Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
